Table 3. National Cancer Institute Common Terminology Criteria for Adverse Events Chemotherapy-Induced Adverse Effects Scores for the Silymarin and Placebo Groups ^a.

Variables	Nano-Silymarin Group (n = 30)	Placebo Group (n = 30)	P-Value b
Neuropathy, at the beginning of the study	0 (0 - 0)	0 (0 - 0)	1
Neuropathy, at the end of course 3	0 (0-0)	1 (1 - 1)	< 0.001 c
Neuropathy, at the end of course 6	1 (0 - 2)	1 (1 - 2)	0.610
HFS, at the beginning of the study	0 (0 - 0)	0 (0 - 0)	1
HFS, at the end of course 3	0 (0 - 0)	1 (0 - 1)	< 0.001 c
HFS, at the end of course 6	1 (0 - 1)	1 (0 - 1.25)	0.022 c

Abbreviations: NCI-CTCAE, National Cancer Institute-Common Terminology Criteria for Adverse Events; HFS, hand-foot syndrome.

^a Values are expressed as median (quartile range).

^b Mann–Whitney test.

^c P < 0.05.